JPRN-UMIN000029991
Completed
Phase 1
A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma - A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma
Yamaguchi University Graduate School of Medicine0 sites20 target enrollmentNovember 20, 2017
Conditionshepatocellular carcinoma
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- hepatocellular carcinoma
- Sponsor
- Yamaguchi University Graduate School of Medicine
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Uncontroled general complication. etc
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancerEUCTR2016-000081-33-DEigartis GmbH42
Completed
Not Applicable
The phase I study of the combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and tumor-specific peptide pulsed dendritic cells for patients with advanced head and neck mucosal melanomaHead and neck mucosal malignant melanomaJPRN-UMIN000011508Department of Otorynolaryngology, Head and Neck Surgery9
Recruiting
Not Applicable
A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancerResected biliary tract cancerJPRN-UMIN000004359Shinshu University School of Medicine, Surgery33
Recruiting
Phase 1
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.glioblastomaMedDRA version: 20.0Level: PTClassification code: 10018337Term: Glioblastoma multiforme Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-508278-26-01Z Brussel18
Recruiting
Phase 2
A randomized phase II trial of adjuvant immunotherapy with alpha-GalactosylCeramide-pulsed dendritic cells for advanced oropharyngeal and hypopharyngeal cancer following standard therapyOropharyngeal and Hypopharyngeal squamous cell carcinomaJPRN-UMIN000007559Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University80